TWTakahito Wada

Takahito Wada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takahito Wada has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • When and how to enlighten citizens on genetics and hereditary cancer: a web survey of online video viewers

    by Reimi Sogawa, Takahito Wada, Noriyuki Yamashita, Mariko Kochi, Mashu Futagawa, Fumino Kato, Yusaku Urakawa, Yayoi Tanimura, Hideki Yamamoto, Shuta Tomida, et al.

    With the rapid expansion of genomic medicine, more citizens are compelled to think about genetics in their daily lives. This study aims to explore appropriate types of educational media and methods to enlighten activities for genetics and hereditary cancer. We presented an 18-min YouTube video on genetics and hereditary cancer to participants at a scientific event, Science Agora 2020, and administered a web questionnaire to investigate their opinions about when and how citizens should start learning about genetics and hereditary cancer. We recruited 133 participants who watched the video, and 26.3% (35/133) responded to the questionnaire. Most of them were evaluated to understand and appreciate the contents of the video. They identified websites, or videos as suitable learning media, irrespective of their sex, age, or profession. They highlighted upper elementary school or junior high school as appropriate educational stages to start learning about genetics and hereditary cancer to facilitate collecting their own genetic information by themselves. Our findings show that educational institutions should provide opportunities to learn about genetics and hereditary cancers, especially for upper elementary school and junior high school students, using learning media, such as videos, depending on their level or demand.


  • Open Access

    When and how to enlighten citizens on genetics and hereditary cancer: A Web survey of online video viewers

    by Reimi Sogawa, Takahito Wada, Noriyuki Yamashita, Mariko Kochi, Mashu Futagawa, Fumino Kato, Yusaku Urakawa, Yayoi Tanimura, Hideki Yamamoto, Shuta Tomida, et al.

    With the rapid expansion of genomic medicine, citizens are compelled to think about genetics in daily life. Therefore, this study aims to explore appropriate types of educational media and methods of enlightenment activities for genetics and hereditary cancer. For this purpose, we launched the public awareness project, planned and run by genetic medicine experts. In this study, we presented an 18-minute YouTube video on genetics and hereditary cancer to participants at Science Agora 2020, and administered a web questionnaire to investigate their opinions about when and how citizens should start learning about genetics and hereditary cancer. We recruited 133 participants who watched the video. Among them, only 35 (26.3%) responded to the questionnaire. Most of the respondents understood and appreciated the contents of the video. They identified websites, videos, manga, and books as suitable learning media, irrespective of sex, age, or profession. Moreover, they highlighted upper elementary school or junior high school as appropriate educational stages to start learning about genetics and hereditary cancer to facilitate collecting their own genetic information by themselves. Our findings show that educational institutions should provide opportunities to learn about genetics and hereditary cancers, especially for upper elementary school and junior high school students, using learning media, such as videos, depending on their level or demand.

  • Open Access

    The ATRX splicing variant c.21-1G>A is asymptomatic

    by Karin Kojima, Takahito Wada, Hiroko Shimbo, Takahiro Ikeda, Eriko F. Jimbo, Hirotomo Saitsu, Naomichi Matsumoto, Takanori Yamagata

    The ATRX variant c.21-1G>A was detected by an exome analysis of a patient with Cockayne syndrome without alpha thalassemia X-linked intellectual disability syndrome (ATR-XS). In addition, variants in ERCC6 were detected. ATRX c.21-1G>A is localized at the splicing acceptor site of intron 1. This splicing event, NM_000489.6: c.21_133del p.S7Rfs*1, induces exon 2 deletion and early termination. The start codon in exon 3 of ATRX is presumed to produce a slightly shorter but functional ATRX protein.


  • Mortality and morbidity of infants with trisomy 21, weighing 1500 grams or less, in Japan

    by Hidenori Kawasaki, Takahiro Yamada, Yoshimitsu Takahashi, Takeo Nakayama, Takahito Wada, Shinji Kosugi, on behalf of the Neonatal Research Network of Japan, Satoshi Kusuda, Masanori Fujimura, Hajime Nakamura, et al.

    Although very low birth weight (VLBW) is well studied in neonatology and the perinatal prognosis of VLBW infants has improved over time, little is known about the prognosis of VLBW infants with trisomy 21 (T21). We aimed to investigate the mortality and morbidity of VLBW infants with T21 during NICU admission in Japan, in comparison to those of infants without birth defects (BD−). Maternal and neonatal data of infants weighing 1500 grams or less admitted to the centers of the Neonatal Research Network of Japan from 2003 to 2016 were collected prospectively. Of 60,136 infants, 328 (0.55%) had T21. Although maternal age in the case of T21 infants was higher, maternal complications tended to be less frequent than in those with BD−. Multivariable analysis revealed that morbidities were higher in infants with T21 than in those with BD− but respiratory distress syndrome and retinopathy of prematurity were less frequent in those with T21 (p < 0.001, and p = 0.014, respectively), and no significant difference was observed between the two groups in the proportion of late-onset circulatory collapse of prematurity as well as cystic periventricular leukomalacia (p = 0.739 and p = 0.733, respectively). The survival rate at discharge from the NICU was 77% and 94% for T21 and BD−, respectively. This was the first nationwide survey of VLBW infants with T21 in Japan. Although there were no data regarding the timing of diagnosis, these data will aid prenatal genetic counseling and perinatal management of T21 infants.

  • Analysis of triptan use during pregnancy in Japan: A case series

    by Yuko Yamaguchi, Takahiro Yamada, Mikako Goto, Hidenori Kawasaki, Takahito Wada, Yasuko Ikeda‐Sakai, Yoshiyuki Saito, Masahiro Hayashi, Shiro Tanaka, Ryosuke Takahashi, et al.

    To evaluate the safety of triptan use during pregnancy in a Japanese population, we descriptively analyzed the data on pregnancy and fetal outcomes from 128 pregnant women using triptans for migraine treatment at two Japanese facilities that provided counseling on drug exposure in pregnancy between 2001 and 2017. The risks of miscarriage, low birth weight, and preterm birth were similar to those reported in the demographic statistics in Japan. The incidence proportion of malformation was also within the baseline risk range. Accumulated data suggest that exposure to triptans during pregnancy does not clearly increase the risk of negative pregnancy and fetal outcomes. This finding can help reduce anxiety in pregnant women with migraines who are taking triptans.


  • Open Access

    Complex hereditary spastic paraplegia associated with episodic visual loss caused by ACO2 variants

    by Takenori Tozawa, Akira Nishimura, Tamaki Ueno, Akane Shikata, Yoshihiro Taura, Takeshi Yoshida, Naoko Nakagawa, Takahito Wada, Shinji Kosugi, Tomoko Uehara, et al.

    Most patients with homozygous or compound heterozygous pathogenic ACO2 variants present with muscular hypotonia features, namely, infantile cerebellar-retinal degeneration. Recently, two studies reported rare familial cases of ACO2 variants presenting as complex hereditary spastic paraplegia (HSP) with broad clinical spectra. Here, we report the case of a 20-year-old Japanese woman with complex HSP caused by compound heterozygous ACO2 variants, revealing a new phenotype of episodic visual loss during febrile illness.


  • Pharmacological prospects of G-quadruplexes for neurological diseases using porphyrins

    by Sefan Asamitsu, Yasushi Yabuki, Susumu Ikenoshita, Takahito Wada, Norifumi Shioda


  • The short-term mortality and morbidity of very low birth weight infants with trisomy 18 or trisomy 13 in Japan

    by Hidenori Kawasaki, Takahiro Yamada, Yoshimitsu Takahashi, Takeo Nakayama, Takahito Wada, Shinji Kosugi, on behalf of the Neonatal Research Network of Japan

    Trisomy 18 (T18) and trisomy 13 (T13) are major concerns in prenatal genetic testing due to their poor prognosis; very low birth weight (VLBW) is also a concern in neonatology. The aim of this study was to investigate the mortality and morbidity of VLBW infants diagnosed with T18/T13 in Japan, compared with those with no birth defects (BD−). Maternal and neonatal data were collected prospectively from infants weighing <1501 g and were admitted to centers of the Neonatal Research Network of Japan during 2003 to 2016. Among 60,136 infants, 563 and 60 was diagnosed with T18 and T13, respectively. Although the age of mothers of infants with T18/T13 was higher, the frequency of maternal complications was lower than those with BD−. With maternal and neonatal characteristic adjustments, T18/T13 had a higher incidence of each morbidity when compared with BD−. Mortality rates in the NICU were 70, 77, and 5.8% for T18, T13, and BD−, respectively, while the survival discharge rates of T18 and T13 were 29.5 and 23.3%, respectively, which was significantly higher than previous reports. This was the first nationwide survey for VLBW infants with T18/T13 in Japan; this novel data will be relevant and useful for prenatal genetic counseling and perinatal management. Although T18/T13 were considered to be fatal in the past, with proper epidemiological information, discussions with affected families, and compassionate patient care, the mortality rate of T18/T13 can be improved.


  • Current status and legal/ethical problems in the research use of the tissues of aborted human fetuses in Japan

    by Hidenori Kawasaki, Takahiro Yamada, Takahito Wada, Shinji Kosugi

    Background To date there is no law regulating the research use of human aborted fetuses in Japan. Objective The aim was to review the current status with historical background and legal/ethical problems limiting the research use of the tissues of aborted human fetuses. Method We reviewed literature via PubMed, Web of Science, Scopus, Japana Centra Revuo Medicina and CiNii, reports from various committees and research groups from Ministry of Health, Labour and Welfare (MHLW), and domestic books. Results Aborted human fetal tissues used for research purposes were first documented in the 1920s. The first guideline, the Peel Code was released in 1972. Since then, in Western countries, the research use of aborted fetuses has been less restricted compared with that of embryos, due to the following guidelines outlined by expert groups. Currently, aborted fetal tissues are commercially available for research purposes in the US. In Japan, only four indications are presented in “a public statement permitting research use of deceased fetuses' and ‘neonates' organs etc.” (1987). In the 2000s, expert committees of the MHLW concluded that research use of human aborted fetuses should be discontinued, and that comprehensive rules and independent regulations should be implemented. This issue has not been discussed in the Japanese legislature since 2003. Discussion Establishment of laws and guidelines for this issue is insufficient not only in Japan but also in other countries. It is important to secure transparency for making laws and guidelines and in obtaining public understanding.